# US 2014/0271690 A1 · Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0271690 A1
- Document ID: US20140271690A1
- Status: Published application
- Kind: A1
- Application number: 13/843,883
- Filed: 2013-03-15
- Published: 2014-09-18
- Earliest claimed: 2013-03-15
- Assignees: United Biomedical, Inc.
- Applicants: United Biomedical, Inc.
- Inventors: Chang Yi Wang
- Web page: https://patentgrep.com/patent/US20140271690A1

## CPC

- C07K 14/4711: {Alzheimer's disease; Amyloid plaque core protein}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 39/0005: {Vertebrate antigens (from snakes A61K39/38)}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 14/34: from Corynebacterium (G)
- C07K 16/18: against material from animals or humans
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/58: {raising an immune response against a target which is not the antigen used for immunisation}
- C12N 2730/10134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/18434: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure is directed to individual Aβ peptide immunogen constructs, peptide compositions comprising these Aβ peptide immunogen constructs and mixtures thereof, pharmaceutical compositions including vaccine formulations comprising these Aβ peptide immunogen constructs, with the individual Aβ peptide immunogen constructs having the N-terminus of the Aβ peptide as the B cell (B) epitopes linked through spacer residue(s) to heterologous T helper cell (Th) epitopes derived from pathogen proteins that act together to stimulate the generation of highly specific antibodies directed against the N-terminus of the Aβ peptide offering protective immune responses to patients at risk for, or with, Alzheimer's Disease.

## Claims

### Claim 1

An Aβ peptide immunogen construct comprising the following formula:
(N-terminal fragment of Aβ1-42 peptide)-(A)o-(Th)-X
wherein (N-terminal fragment of Aβ1-42 peptide) is a B cell epitope from Aβ comprising about 10 to about 14 amino acid residues selected from the group consisting of SEQ ID NOs: 4, 5, and 6;
each A is independently an amino acid or a linking group selected from the group consisting of an amino acid, Lys-, Gly-, Lys-Lys-Lys-, (α, ε-N)Lys, and ε-N-Lys-Lys-Lys-Lys (SEQ ID NOs: 32);
each Th comprises an amino acid sequence that constitutes a helper T cell epitope selected from the group consisting of SEQ ID NOs: 34, 37, 38, 40 to 47 and functional immunological analogues thereof;
X is an α-COOH or α-CONH2 of an amino acid; and
o is from 0 to about 4.

### Claim 2 (depends on 1)

The Aβ peptide immunogen construct of claim 1, wherein the (N-terminal fragment of Aβ1-42 peptide) is Aβ1-14 (SEQ ID NO: 4).

### Claim 3 (depends on 1)

The Aβ peptide immunogen construct of claim 1, wherein A is ε-N-Lys-Lys-Lys-Lys (SEQ ID NOs: 32).

### Claim 4 (depends on 1)

The Aβ peptide immunogen construct of claim 1, wherein the Th epitope is SEQ ID NOs: 45 or 46.

### Claim 5 (depends on 1)

The Aβ peptide immunogen construct of claim 1, comprising the amino acid sequence of SEQ ID NOs: 48-65.

### Claim 6 (depends on 1)

The Aβ peptide immunogen construct of claim 1, consisting essentially of the amino acid sequences of SEQ ID NOs: 62-65.

### Claim 7 (depends on 1)

The Aβ peptide immunogen construct of claim 1 that is SEQ ID NOs: 62, 63, 64, and/or 65.

### Claim 8 (depends on 1)

A composition comprising the Aβ peptide immunogen construct of claim 1.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising
a. the Aβ peptide immunogen construct of claim 1; and
b. a pharmaceutically acceptable delivery vehicle and/or adjuvant.

### Claim 10 (depends on 1)

An Alzheimer's Disease vaccine composition comprising
a. the Aβ peptide immunogen construct of claim 1; and
b. a pharmaceutically acceptable delivery vehicle and/or adjuvant.

### Claim 11 (depends on 7)

An Alzheimer's Disease vaccine composition comprising
a. the Aβ peptide immunogen construct of claim 7; and
b. a pharmaceutically acceptable delivery vehicle and/or adjuvant.

### Claim 12 (depends on 10)

The Alzheimer's Disease vaccine composition of claim 10, wherein the adjuvant in (b) is a mineral salt of Aluminum selected from the group consisting of alhydrogel (Al(OH)3) or adjuphos (AlPO4).

### Claim 13 (depends on 10)

The Alzheimer's Disease vaccine composition of claim 10, wherein the peptide antigen in (a) is mixed with an CpG oligodeoxynucleotide (ODN) to form a stabilized immunostimulatory complex.

### Claim 14 (depends on 1)

An isolated antibody or epitope-binding fragment thereof which binds to the (N-terminal fragment of Aβ1-42 peptide) component of the Aβ peptide immunogen construct of claim 1.

### Claim 15 (depends on 14)

The isolated antibody or epitope-binding fragment thereof of claim 14, which specifically binds to Aβ1-10 (SEQ ID NO: 6).

### Claim 16 (depends on 1, 14)

The isolated antibody or epitope-binding fragment thereof of claim 14, bound to the Aβ peptide immunogen construct of claim 1.

### Claim 17 (depends on 15)

The isolated antibody or epitope-binding fragment thereof of claim 15, bound SEQ ID NO: 6.

### Claim 18 (depends on 14)

A composition comprising the isolated antibody or epitope-binding fragment thereof of claim 14.

### Claim 19 (depends on 10)

A method of reducing the severity or delaying onset of dementia in human patients comprising administering a vaccine formulation according to claim 10.

### Claim 20 (depends on 19)

The method of claim 19, wherein said vaccine formulation is administered in an aqueous solution comprising between 101 ug and 1000 ug per dose to patients at risk for, or with, AD.
